Phenolic and quinone methide nor-triterpenes as selective NLRP3 inflammasome inhibitors

Dysregulated inflammasome activity, particularly of the NLRP3 inflammasome, is associated with the development of several inflammatory diseases. The study of molecules directly targeting NLRP3 is an emerging field in the discovery of new therapeutic compounds for the treatment of inflammatory disord...

Descripción completa

Detalles Bibliográficos
Autores: Estévez Braun, Ana María, González-Cofrade, Laura, Green, Jack P., Cuadrado, Irene, Amesty Arrieta, Ángel Ernesto, Oramas-Royo, Sandra M., Brough, David, Hortelano, Sonsoles, Heras, Beatriz de las
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad de La Laguna (ULL)
Repositorio:RIULL. Repositorio Institucional de la Universidad de La Laguna
OAI Identifier:oai:riull.ull.es:915/40664
Acceso en línea:http://riull.ull.es/xmlui/handle/915/40664
Access Level:acceso abierto
Palabra clave:Nor-friedelane triterpenes
NLRP3 inflammasome
macrophages
Maytenus retusa
ASC
pyroptosis
IL-1b
Descripción
Sumario:Dysregulated inflammasome activity, particularly of the NLRP3 inflammasome, is associated with the development of several inflammatory diseases. The study of molecules directly targeting NLRP3 is an emerging field in the discovery of new therapeutic compounds for the treatment of inflammatory disorders. Friedelane triterpenes are biologically active phytochemicals having a wide range of activities including anti-inflammatory effects. In this work, we evaluated the potential anti-inflammatory activity of phenolic and quinonemethide nor-triterpenes (1-11) isolated from Maytenus retusa and some semisynthetic derivatives (12-16) through inhibition of the NLRP3 inflammasome in macrophages. Among them, we found that triterpenes 6 and 14 were the most potent, showing markedly reduced caspase-1 activity, IL-1β secretion (IC50 = 1.15 µM and 0.19 µM, respectively), and pyroptosis (IC50 = 2.21 µM and 0.13 µM, respectively). Further characterization confirmed their selective inhibition of NLRP3 inflammasome in both canonical and non-canonical activation pathways with no effects on AIM2 or NLRC4 inflammasome activation.